Resources from the same session
Safety and activity of the pan–fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with advanced urothelial carcinoma
Presenter: Jean-Charles Soria
Session: Genitourinary tumours, non-prostate
Resources:
Abstract
Quality of life (QoL) and neurotoxicity in germ-cell cancer survivors (GCCS)
Presenter: Jakob Lauritsen
Session: Genitourinary tumours, non-prostate
Resources:
Abstract
Phase 1b dose-finding study of avelumab (anti-PD-L1) + axitinib in treatment-naïve patients with advanced renal cell carcinoma
Presenter: James Larkin
Session: Genitourinary tumours, non-prostate
Resources:
Abstract
Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study
Presenter: Arjun Balar
Session: Genitourinary tumours, non-prostate
Resources:
Abstract
Large retroperitoneal lymphadenopathy (RPLN) and increased risk of venous thromboembolism (VTE) in patients (pts) with metastatic germ cell tumours (mGCT): a global germ cell cancer group (G3) study
Presenter: Ben Tran
Session: Genitourinary tumours, non-prostate
Resources:
Abstract
Invited discussant abstracts 781PD and 782PD
Presenter: Aristotelis Bamias
Session: Genitourinary tumours, non-prostate
Resources:
Presentation
Webcast
Invited discussant abstracts 777PD, 778PD, 779PD and 780PD
Presenter: Christian Kollmannsberger
Session: Genitourinary tumours, non-prostate
Resources:
Presentation
Webcast
Interim analysis of a phase I dose escalation trial of the antibody drug conjugate (ADC) AGS15E (ASG-15ME) in patients (Pts) with metastatic urothelial cancer (mUC)
Presenter: Daniel Petrylak
Session: Genitourinary tumours, non-prostate
Resources:
Abstract
IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC)
Presenter: Joaquim Bellmunt
Session: Genitourinary tumours, non-prostate
Resources:
Abstract
Immunotherapy will be “THE OPTION” in first and second line urothelial tumors
Presenter: Laurence Albiges
Session: Genitourinary tumours, non-prostate
Resources:
Presentation
Webcast